~ Buy the IXEMPRA KIT (ixabepilone) Drug Profile, 2024 PDF Report in the Report Store ~

IXEMPRA KIT Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Ixempra Kit, and what generic alternatives are available?

Ixempra Kit is a drug marketed by R-pharm Us Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-six countries.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ixabepilone profile page.

DrugPatentWatch^® Generic Entry Outlook for Ixempra Kit

Ixempra Kit was eligible for patent challenges on October 16, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 21, 2025. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for IXEMPRA KIT?
What are the global sales for IXEMPRA KIT?
What is Average Wholesale Price for IXEMPRA KIT?

Summary for IXEMPRA KIT

International Patents:	34
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	55
Patent Applications:	6,496
Drug Prices:	Drug price information for IXEMPRA KIT
DailyMed Link:	IXEMPRA KIT at DailyMed

Drug patent expirations by year for IXEMPRA KIT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IXEMPRA KIT

Generic Entry Date for IXEMPRA KIT^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 022065 Dosage: INJECTABLE;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IXEMPRA KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
R-Pharm-US, LLC	Phase 2
R-Pharm US, Inc.	Phase 2
Yale University	Phase 2

See all IXEMPRA KIT clinical trials

Paragraph IV (Patent) Challenges for IXEMPRA KIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IXEMPRA KIT	Injection	ixabepilone	15 mg/vial and 45 mg/vial, single- use vials	022065	1	2012-04-16

US Patents and Regulatory Information for IXEMPRA KIT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for IXEMPRA KIT

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for IXEMPRA KIT

See the table below for patents covering IXEMPRA KIT around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Taiwan	I250017		⤷ Sign Up
European Patent Office	1353667		⤷ Sign Up
Norway	335119		⤷ Sign Up
Malaysia	124151	EPOTHILONE DERIVATIVES	⤷ Sign Up
Israel	156988		⤷ Sign Up
Canada	2434566		⤷ Sign Up
Bulgaria	66494		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for IXEMPRA KIT

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1019389	C01019389/01	Switzerland	⤷ Sign Up	PRODUCT NAME: IXABEPILONE; REGISTRATION NUMBER/DATE: SWISSMEDIC 58880 27.02.2009
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description